Hepatocellular carcinoma therapy finds a channel on the radio
This EBioMedicine commentary discusses tumour-specific amplitude-modulated RF EMF as an anti-cancer therapy for hepatocellular carcinoma and highlights Cav3.2 (CACNA1H) T-type calcium channels as a proposed mediator of the effect. It notes that the reported whole-body averaged SAR in a treated HCC patient was below international safety standards and describes supporting animal and cell experiments at similar SAR levels. The piece emphasizes open mechanistic and clinical questions and calls for further studies, including interactions with calcium channel blocker medications.
Key points
- The article is a commentary on studies reporting anti-HCC effects from tumour-specific amplitude-modulated RF EMF exposure.
- Cav3.2 (CACNA1H) T-type calcium channels are described as key calcium entry proteins mediating the reported anti-HCC effects.
- Calcium influx through Cav3.2 is reported to initiate down-regulation of HCC cancer stem cells in the summarized work.
- Normal hepatocytes are stated to be unaffected by AM RF EMF in the described experiments.
- Whole-body averaged SAR in an HCC patient receiving AM RF EMF is reported to be below international safety standards.
- The commentary highlights uncertainties about in vivo mechanism, tumour specificity, and channel selectivity, and suggests further mechanistic and epidemiologic studies.
- It recommends avoiding calcium channel blockers during treatment because they may block the reported anticancer effects.
Referenced studies & papers
Relevant papers in OpenMel
Source:
Open original
AI-generated summaries may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.
AI-generated summaries may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.
Comments
Log in to comment.
No comments yet.